Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $72,000.

  • Catalyst Pharmaceuticals' Depreciation & Amortization (CF) fell 32.08% to $72,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $417,000, marking a year-over-year increase of 13.62%. This contributed to the annual value of $397,000 for FY2024, which is 25.63% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $72,000 for Q3 2025, which was down 37.93% from $116,000 recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Depreciation & Amortization (CF) peaked at $116,000 during Q2 2025, and registered a low of $31,000 during Q2 2021.
  • Its 3-year average for Depreciation & Amortization (CF) is $92,364, with a median of $86,000 in 2024.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Depreciation & Amortization (CF) surged by 592.86% in 2021, and later crashed by 64.95% in 2022.
  • Catalyst Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $33,000 in 2021, then increased by 6.06% to $35,000 in 2022, then surged by 140.00% to $84,000 in 2023, then soared by 35.71% to $114,000 in 2024, then slumped by 32.08% to $72,000 in 2025.
  • Its last three reported values are $72,000 in Q3 2025, $116,000 for Q2 2025, and $115,000 during Q1 2025.